Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057140 | 1.00 | TSHR (0.49) | TSHRHTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL21057170 | 0.84 | LDHA (0.40) | TSHRKMT2ASMN1; SMN2LMNAATM | |
| SCHEMBL21059512 | 0.84 | LMNA (0.44) | TSHRKMT2ASMN1; SMN2LMNAATM | |
| SCHEMBL21057167 | 0.84 | LDHA (0.40) | TSHRKMT2ASMN1; SMN2LMNAATM | |
| SCHEMBL21059511 | 0.84 | LMNA (0.44) | TSHRKMT2ASMN1; SMN2LMNAATM | |
| SCHEMBL21057246 | 0.83 | SMN1; SMN2 (0.58) | TSHRHTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL7826588 | 0.83 | SMN1; SMN2 (0.58) | TSHRHTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL23368020 | 0.82 | TSHR (0.67) | TSHRHTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL18331136 | 0.82 | TSHR (0.50) | TSHRHTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL3602820 | 0.82 | TSHR (0.50) | TSHRHTR2AHTR2CHTR2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723745-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | claimed |
| CN-111587109-A | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-08-25 | — | — | CN | claimed |
| WO-2019115777-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | claimed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | claimed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | claimed |
| EP-3723745-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-06-19 | — | — | EP | disclosed |
| CN-111491628-B | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2023-10-13 | — | — | CN | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11591284-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-02-28 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| CN-111491628-A | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-08-04 | — | — | CN | disclosed |
| WO-2019115780-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019115777-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019115777-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | TSHR 3626/4885HTR2A 3861/4885HTR2C 4504/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | TSHR 3626/4885HTR2A 3861/4885HTR2C 4504/4885 |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CPT1B, CLCN2, CACNB1 | TSHR 3912/4885HTR2A 3420/4885HTR2C 3861/4885 |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | TSHR 3626/4885HTR2A 3861/4885HTR2C 4504/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | TSHR 3626/4885HTR2A 3861/4885HTR2C 4504/4885 |
| US-11591284-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, CACNA1S | TSHR 4324/4885HTR2A 3734/4885HTR2C 4093/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | TSHR 3626/4885HTR2A 3861/4885HTR2C 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.